Participation in other studies involving investigational drug(s) within  days prior to study entry.
Participation in any other clinical trial involving another investigational agent within  weeks prior to Day  of the study.
Participation in other studies involving investigational drug(s) within  weeks prior to study entry
Are currently enrolled in, or have discontinued within  days of screening, from a clinical trial involving an investigational product or non-approved use of a drug or device.
Participation in any study involving administration of an investigational agent within  days of randomization into this study
Have participated, within the last  days in a clinical trial involving an investigational product or are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
Current enrollment in another clinical study involving treatment and/or is receiving an investigational agent for any reason, or use of any investigational agents within  days of initiating study treatment.
Participation in any other clinical trial involving another investigational agent within  weeks prior to first dose of study agent
Participation in any other clinical trial involving another investigational agent within  weeks prior to first dosing of study drug
Participation in any other research protocol involving administration of an investigational agent within  month prior to study entry
Participation in any other clinical trial involving another investigational agent within  weeks prior to first immunization
Participation in another clinical study involving an investigational product within  month before study entry;
Subjects may not be receiving any other investigational agents or have participated in any other clinical trial involving another investigational agent for treatment of advanced solid tumors or lymphoma within  weeks prior to cycle , day  of the study.
Are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
Participation in any other clinical trial involving another investigational agent for the treatment of AML within  weeks prior to day  of the study or at least  half-lives of the investigational agent, whichever is shorter
Participation in other studies involving investigational drug(s) (phases -) within  weeks before randomization in the current study
Participation to a study involving a medical or therapeutic intervention in the last  days
Participation in a clinical study involving receipt of an investigational drug during the last  days.
Use of GSK (CPHPC), or participation in a separate clinical trial involving CPHPC within  months of screening
Previous treatment with crenolanib or prior participation in clinical trial involving crenolanib.
Participation in any previous study involving sipuleucel-T
Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study
Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study
Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study
Prior treatment in any other clinical trial involving another investigational agent within  weeks prior to Day - of the study; resolution of respective adverse event to Grade  or lower should have occurred
Are currently receiving treatment in a clinical trial involving an investigational product or non-approved use of a drug or device.
Participation in a clinical trial involving an investigational drug within  days of study start
The participant is currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device.
Participation in any other research protocol involving administration of an investigational agent within  weeks prior to study entry
Concurrent investigational therapy given to treat cancer or concurrent participation in another clinical trial involving anti-cancer investigational drug.
Current enrollment in another clinical trial involving treatment and/or is receiving an investigational agent for any reason
Current enrollment in another clinical trial involving treatment and/or is receiving an investigational agent for any reason
Participant has participated in another clinical study involving an investigational product (IP) or investigational device within  days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
Participation in any other clinical trial involving another investigational agent within  weeks prior to day  of the study.
Is concurrently enrolled in another therapeutic clinical trial involving ongoing therapy with any investigational or marketed product or placebo.
Participation in any other clinical trial involving another investigational agent within  weeks prior to first dosing of study drug
Enrolled in a clinical trial involving an investigational product or nonapproved use of a drug or in medical research judged not to be scientifically or medically compatible with this study.
Concurrent participation in another study involving investigational drugs or investigational medical devices
Participation in another clinical trial involving an investigational product within  days prior to screening; or
Previous participation in any clinical trial involving rolapitant
Participation in another clinical trial involving an investigational agent within  weeks of enrollment
Participant in a clinical trial involving an investigational drug within the past  days
Patient has completed participation in another clinical study involving administration of an investigational agent in the preceding  weeks. However, participation in clinical studies involving other investigational PET or SPECT tracers will not be excluded if in the opinion of the Investigator:
Patient included in another clinical trial involving an IMP within  days before the first investigational contrast agent injection.
